Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 2/2012

01-04-2012 | Review Article

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

Authors: Ronny S. Jiji, MD, Christopher M. Kramer, MD, Michael Salerno, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 2/2012

Login to get access

Abstract

Cardiotoxicity due to administration of cancer therapeutic agents such as anthracyclines and herceptin are well described. Established guidelines to screen for chemotherapy-related cardiotoxicity (CRC) are primarily based on serial assessment of left ventricular (LV) ejection fraction (EF). However, other parameters such as LV volume, diastolic function, and strain may also be useful in screening for cardiotoxicity. More recent advances in molecular imaging of apoptosis and tissue characterization by cardiac MRI are techniques which might allow early detection of patients at high risk for developing cardiotoxicity prior to a drop in EF. This comprehensive multi-modality review will discuss both the current established imaging techniques as well as the emerging technologies which may revolutionize the future of screening and evaluation for CRC.
Literature
1.
Horenstein MS, Vander Heide RS, L’Ecuyer TJ. Molecular basis of anthracycline-induced cardiomyopathy and its prevention. Mol Genet Metab 2000;71:436-44.PubMedCrossRef
2.
Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: The critical role of energetics. J Mol Cell Cardiol 2006;41:389-405.PubMedCrossRef
3.
Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
4.
Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein polymorphisms are associated with doxorubicin-induced cardiomyopathy. Circulation 2005;112:3754-62.PubMedCrossRef
5.
Minotti G, Saponiero L, Licata S, Menna P, Calafiore AM, Teodori G, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001;7:1511-5.PubMed
6.
Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin’s lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486-93.PubMedCrossRef
7.
Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.PubMedCrossRef
8.
Hudis C. Traztuzumab—mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.PubMedCrossRef
9.
Crone SA, Zhao Y, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65.PubMedCrossRef
10.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:784-92.CrossRef
11.
Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, Goldhirsch A, Untuch M, Smith I, et al. Traztuzumab after adjunctive chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-71.PubMedCrossRef
12.
Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies. Are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-50.PubMedCrossRef
13.
Kalay N, Basar E, Ozdrogu I, ER O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. JACC 2006;48:2258-62.PubMed
14.
Santos DL, Moreno AJM, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002;185:218-27.PubMedCrossRef
15.
Cardinale D, Sandri MT, Martinoni A, Tricca A, Lamantia G, Cinieri S, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. JACC 2000;36:517-22.PubMed
16.
Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC 2010;55:213-20.PubMed
17.
Ewer MS, Vooletich MT, Durand J, Woods ML, Davis JR, Valero V, et al. Reversibility of traztuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6.PubMedCrossRef
18.
19.
Schwartz RG, McKenzie WB, Alexander J, Sager P, Manatunga A, Schwartz PE, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 1987;82:1109-18.PubMedCrossRef
20.
McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048-56.PubMedCrossRef
21.
Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol 1984;2:112-7.PubMed
22.
Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-22.PubMedCrossRef
23.
Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant traztuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.PubMedCrossRef
24.
Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2007;97:318-26.CrossRef
25.
Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Tsao A, Wang Y, et al. Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computer tomography. Mol Imaging 2008;3:132-8.
26.
27.
28.
van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996;77:843-50.PubMedCrossRef
29.
Mitani I, Jain D, Joska TM, Burtness B, Zaret B. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10:132-9.PubMedCrossRef
30.
31.
Muntinga HJ, van den Berg F, Knol HR, Niemeyer MG, Blanksma PK, Louwes H, et al. Normal values and reproducibility of left ventricular filling parameters by radionuclide angiography. Int J Card Imaging 1997;13:165-71.PubMedCrossRef
32.
Lee KJ, Southee AE, Bautovich GJ, Freedman B, McLaughlin AF, Rossleigh MA, et al. Normalised radionuclide measures of left ventricular diastolic function. Eur J Nucl Med 1989;15:123-7.PubMedCrossRef
33.
Kusuoka H, Futaki S, Koretsune Y, Kitabatake A, Suga H, Kamada T, et al. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc Pharmacol 1991;18:437-44.PubMedCrossRef
34.
Pelikan PCD, Weisfeldt ML, Jacobus WE, Miceli MV, Bulkley BH, Gerstenblith G. Acute doxorubicin cardiotoxicity: Functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. J Cardiovasc Pharmacol 1986;8:1058-66.PubMedCrossRef
35.
Cottin Y, Touzery C, Coudert B, Gilles A, Walker P, Massing JL, et al. Impairment of diastolic function during short-term anthracycline therapy. Br Heart J 1995;73:61-4.PubMedCrossRef
36.
Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic system in man. J Nucl Med 1987;28:1620-4.PubMed
37.
Arimoto T, Takeishi Y, Niizeki T, Koyama Y, Okuyama H, Nozaki N, et al. Ongoing myocardial damage relates to cardiac sympathetic nervous disintegrity in patients with heart failure. Ann Nucl Med 2005;19:535-40.PubMedCrossRef
38.
Carrió I, Estorch M, Berná L, López-Pousa J, Tabernero J, Torres G. Indium-111-Antimyosin and Iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.PubMed
39.
Lekakis J, Prassopoulos V, Athanassiadis P, Kostamis P, Moulopoulos S. Doxorubicin-induced cardiac neurotoxicity: Study with 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol 1996;3:37-41.PubMedCrossRef
40.
Valdés Olmos RA, ten Bokkel Huinink WW, ten Hoeve RFA, van Tinteren H, Bruning PF, van Vlies B, et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer 1995;31A:26-31.PubMedCrossRef
41.
Angerstein C, Behr TM, Behe M, Becker W. Kit formulation for In-111-labeled traztuzumab (Herceptin) for immunoscintigraphy of metastatic breast cancer expressing the HER2/neu receptor [abstract]. Eur J Nucl Med 2000;27:916.
42.
Lub-De Hooge MN, Kosterink JG, Perik PG, Nijnuis H, Tran L, Bart J, et al. Preclinical characterization of 111-In DTPA-traztuzumab. Br J Pharmacol 2004;143:99-106.PubMedCrossRef
43.
44.
de Korte MA, de Vries EGE, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WTA, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007;43:2046-51.PubMedCrossRef
45.
Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WTA, de Korte MA, Jonkman S, et al. Indium-111-labeled traztuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276-82.PubMedCrossRef
46.
Kaderli AA, Baran I, Aydin O, Bicer M, Akpinar T, Ozkalemkas F, et al. Diffuse involvement of the heart and great vessels in primary cardiac lymphoma. Eur J Echocardiogr 2010;11:74-6.PubMedCrossRef
47.
Lee JC, Platts DG, Huang YT, Slaughter RE. Positron emission tomography combined with computed tomography as an integral component in evaluation of primary cardiac lymphoma. Clin Cardiol 2010;33:106-8.CrossRef
48.
Weijs LE, Arsos G, Baarslag HJ, Wittebol S, de Klerk JM. Pericardial involvement in a non-Hodgkin lymphoma patient: Coregistered FDG-PET and CT imaging. Eur Heart J 2007;28:2698.PubMedCrossRef
49.
Nony P, Guastalla J, Rebattu P, Landais P, Lievre M, Bontemps L, et al. In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy. Chemother Pharmacol 2000;45:375-80.CrossRef
50.
Kenk M, Thackeray JT, Thorn SL, Dhami K, Chow BJ, Ascah KJ, et al. Alterations of pre- and post-synaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. J Nucl Cardiol 2010;17:254-63.PubMedCrossRef
51.
Guendouz S, Buicuic O, Kirsch M, Benaiem N, Poulard JE, Deux JF, et al. Restrictive cardiomyopathy associated with left ventricle and left atria endocardial calcifications following chemotherapy. J Am Coll Cardiol 2011;57:1633.PubMedCrossRef
52.
Karabay CY, Kocabay G, Kalayci A, Zehir R, Tanboga H. Mitral regurgitation due to papillary muscle dyssynchrony during traztuzumab treatment. Cardiology 2010;117:296-300.PubMedCrossRef
53.
Hoffman R, von Bardelben S, ten Cate F, Borges AC, Kasprzak J, Firschke C, et al. Assessment of systolic left ventricular function: A multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J 2005;26:607-16.CrossRef
54.
Hundley WG, Kizilbash AM, Afridi I, Franco F, Peshock RM, Grayburn PA. Administration of intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: Comparison with cine magnetic resonance imaging. J Am Coll Cardiol 1998;32:1426-32.PubMedCrossRef
55.
Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol 2004;44:878-86.PubMedCrossRef
56.
Bull SC, Main ML, Stevens GR, Goldman JH, Constable SA, Becher H. Cardiac toxicity screening by echocardiography in normal volunteers: A study of the effects of diurnal variation and use of a core laboratory on the reproducibility of left ventricular measurement. Echocardiography 2011;28:502-7.PubMedCrossRef
57.
Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJS, Cleland JGF, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? Eur Heart J 2000;21:1387-96.PubMedCrossRef
58.
Cottin Y, L’huiller I, Casasnovas O, Geoffroy C, Caillot D, Zeller M, et al. Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Eur J Echocardiogr 2000;1:180-3.PubMedCrossRef
59.
Wassmuth R, Lentszch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging- a pilot study. Am Heart J 2001;141:1007-13.PubMedCrossRef
60.
Karakurt C, Kocak G, Ozgen U. Evaluation of the left ventricular function with tissue tracking and tissue doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography 2008;25:880-7.PubMedCrossRef
61.
Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: The role of diastolic function. Heart 2004;90:1214-6.PubMedCrossRef
62.
Monin JL, Monchi M, Gest V, Duval-Moulin AM, Dubois-Rande JL, Gueret P. Aortic stenosis with severe left ventricular dysfunction and low transvalvular pressure gradients: Risk stratification by low-dose dobutamine echocardiography. J Am Coll Cardiol 2001;37:2101-7.PubMedCrossRef
63.
Guimaraes-Filho F, Tan D, Braga J, Rodrigues A, Waib P, Matsubara B. Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines. Am J Cardiol 2007;100:1303-6.PubMedCrossRef
64.
Bountioukos M, Doorduijn JK, Roelandt JR, Vourvouri EC, Bax JJ, Schinkel AF, et al. Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. Eur J Echocardiogr 2003;4:300-5.PubMedCrossRef
65.
Koyama J, Falk RH. Prognostic significance of strain doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010;3:333-42.PubMedCrossRef
66.
Correia E, Rodrigues B, Santos LF, Moreira D, Gama P, Cabral C, et al. Longitudinal left ventricular strain in hypertrophic cardiomyopathy: Correlation with nonsustained ventricular tachycardia. Echocardiography 2011;7:709-14.CrossRef
67.
Bansal M, Jeffriess L, Leano R, Mundy J, Marwick TH. Assessment of myocardial viability at dobutamine echocardiography by deformation analysis using tissue velocity and speckle-tracking. JACC Cardiovasc Imaging 2010;3:121-31.PubMedCrossRef
68.
Mavinkurve-Groothius AMC, Groot-Loonen J, Marcus KA, Bellersen L, Feuth T, Bökkerink JPM, et al. Myocardial strain and strain rate in monitoring subclinical heart failure in asymptomatic long-term survivors of childhood cancer. Ultrasound Med Biol 2010;36:1783-91.CrossRef
69.
Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with traztuzumab. Am Heart J 2009;158:294-301.PubMedCrossRef
70.
Jurcut R, Wildiers H, Ganame J, D’hooge J, De Backer J, Denys H, et al. Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 2008;21:1283-9.PubMedCrossRef
71.
Wong CY, O’Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004;110:3081-7.PubMedCrossRef
72.
Mizayaki S, Daimon M, Mizayaki T, Onishi Y, Koiso Y, Nishizaki Y, et al. Global longitudinal strain in relation to the severity of aortic stenosis: A two-dimensional speckle tracking study. Echocardiography 2011;28:703-8.CrossRef
73.
Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Feiner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-5.PubMedCrossRef
74.
Takamura T, Dohi K, Onishi K, Tanabe M, Sugiura E, Nakajima H, et al. Left ventricular contraction-relaxation coupling in normal, hypertrophic, and failing myocardium quantified by speckle-tracking global strain and strain rate imaging. J Am Soc Echocardiogr 2010;23:747-54.PubMedCrossRef
75.
Voigt JU, Arnold MF, Karlsson M, Hübbert L, Kukulski T, Hatle L, et al. Assessment of regional longitudinal myocardial strain rate derived from doppler myocardial imaging indexes in normal and infracted myocardium. J Am Soc Echoardiogr 2000;13:588-98.CrossRef
76.
Marwick TH, Leano RL, Brown J, Sun JP, Hoffman R, Lysansky P, et al. Myocardial strain measurement with 2-dimensional speckle tracking echocardiography. Definition of normal range. J Am Coll Cardiol Imaging 2009;2:80-4.
77.
Lindqvist P, Morner S, Henein MY. Cardiac mechanisms of underlying normal exercise tolerance: Gender Impact. Eur J Appl Physiol 2011;112:451-9.PubMedCrossRef
78.
Lawton JS, Cupps BP, Knutsen AK, Ma N, Brady BD, Reynolds LM, et al. Magnetic resonance imaging detexts significant sex differences in human myocardial strain. Biomed Eng Online 2011;10:76.PubMedCrossRef
79.
ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR. Appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J Am Coll Cardiol 2006;48:1475-97.CrossRef
80.
Cranney GB, Lotan CS, Dean L, Baxley W, Bouchard A, Pohost GM. Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging. Validation by calibrated ventricular angiography. Circulation 1990;82:154-63.PubMedCrossRef
81.
Zagrosek A, Abdel-Aty H, Boyé P, Wassmuth R, Messroghli D, Utz W, et al. Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. J Am Coll Cardiol Imaging 2009;2:131-8.
82.
Abdel-Aty H, Zagrosek A, Schulz-Menger J, Taylor AJ, Messroghli D, Kumar A, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 2004;109:2411-6.PubMedCrossRef
83.
Assomull RG, Lyne JC, Keenan N, Gulati A, Bunce NH, Davies SW, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Hear J 2007;28:1242-9.CrossRef
84.
Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979;63:827-34.PubMed
85.
Wagner A, Marholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study. Lancet 2003;361:374-9.PubMedCrossRef
86.
Marholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: A comparison to histology and molecular pathology. Circulation 2004;109:1250-8.CrossRef
87.
Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in traztuzumab induced cardiomyopathy. J Cardiovasc Mag Res 2008;10:5.CrossRef
88.
Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T 1 mapping. J Am Coll Cardiol 2008;52:1574-80.PubMedCrossRef
89.
Maciera AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.CrossRef
90.
Tham EB, Chow K, Spavor M, Pagano JJ, Haykowsky M, Thompson R. Degree of diffuse fibrosis measured by cardiac MRI correlates with LV remodeling in childhood cancer survivors after anthracycline chemotherapy [abstract]. J Cardiovasc Magn Reson 2011;13:P276.CrossRef
91.
Steel K, Broderick R, Gandla V, Larose E, Resnic F, Jerosch-Herold M, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation 2009;120:1390-400.PubMedCrossRef
92.
Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-87.PubMedCrossRef
93.
Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369-74.PubMedCrossRef
94.
Mekinian A, Lions C, Leleu X, Duhamel A, Lamblin N, Coiteux V, et al. Prognosis assessment of cardiac involvement of systemic AL amyloidosis by magnetic resonance imaging. Am J Med 2010;123:864-8.PubMedCrossRef
95.
Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.PubMedCrossRef
96.
Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS, Sampaio RO, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 2010;56:278-87.PubMedCrossRef
97.
Zhang R, Lu W, Wen X, Huang M, Zhou M, Liang D, et al. Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med 2011;52:958-64.PubMedCrossRef
98.
Blankenberg F. To scan or not to scan, it is a question of timing: Technetium-99m-annexin v radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin Cancer Res 2002;8:2757-8.PubMed
99.
Min P, Lim S, Kang S, Hong S, Hwang K, Chung K, et al. Targeted ultrasound imaging of apoptosis with annexin A5 microbubbles in acute doxorubicin-induced cardiotoxicity. J Cardiovasc Ultrasound 2010;18:91-7.PubMedCrossRef
100.
Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden J, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med 2004;45:842-8.PubMed
101.
Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.PubMedCrossRef
102.
Westwood M, Anderson LJ, Firmin DN, et al. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003;18:33-9.PubMedCrossRef
103.
Dash R, Chung J, Chan T, Yamada M, Barral J, Nishimura D, et al. A molecular MRI probe to detect treatment of cardiac apoptosis in vivo. Magn Reson Med 2011;66:1152-62.PubMedCrossRef
104.
Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982;50:32-41.PubMedCrossRef
Metadata
Title
Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs
Authors
Ronny S. Jiji, MD
Christopher M. Kramer, MD
Michael Salerno, MD, PhD
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Journal of Nuclear Cardiology / Issue 2/2012
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-012-9512-2

Other articles of this Issue 2/2012

Journal of Nuclear Cardiology 2/2012 Go to the issue

Original Article

A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease

Editorial Point of View

Towards personalized myocardial viability testing: Personal reflections

Review Article

A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department

Editorial

Acute chest pain of uncertain etiology, the short and long view

Original Article

Yield of a novel ultra-low-dose computed tomography device mounted on a dedicated cardiac SPECT system in improving the accuracy of myocardial perfusion imaging and the detection of chest abnormalities

Original Article

Fully automated wall motion and thickening scoring system for myocardial perfusion SPECT: Method development and validation in large population

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits